Last updated: August 12, 2025
Introduction
China Patent CN108135854, titled "Anti-tumor Agent," pertains to a specific class of pharmaceutical innovations aimed at treating tumors. As of its publication, it represents a strategic piece within China's burgeoning biotechnology patent environment, emphasizing targeted cancer therapies. This analysis offers an exhaustive review of the patent's scope, claims, potential landscape, and strategic implications for stakeholders.
Patent Overview and Context
Filed by a Chinese applicant and published in 2018, CN108135854 claims a novel anti-tumor agent comprising specific chemical structures or biological molecules with demonstrated efficacy in inhibiting tumor cell growth. Its core innovation resides in the compound's unique structure, method of preparation, or application in therapeutic regimens.
The patent exists within China's rapidly expanding biotech patent environment, characterized by increased patent filings aimed at innovative cancer treatments. As of 2023, China ranks second globally in biotech patent applications, with a marked focus on anti-cancer agents [1]. The patent landscape is competitive, with key players including domestic firms such as BeiGene, Innovent, and international pharmaceutical giants.
Scope of the Patent
Technical Field
CN108135854 falls within the pharmaceutical and biotech sectors—specifically targeting oncological therapeutics. It emphasizes small-molecule compounds or biologics designed to interfere with tumor growth pathways.
Patent Claims Analysis
The patent encompasses a series of claims defining the scope of protection, which can be broadly categorized into:
-
Compound Claims:
- These claims define the chemical entities, often including specific structural formulas, substituents, and stereochemistry.
- For example, compounds with a particular core scaffold linked to functional groups that enhance anti-tumor activity.
-
Use Claims:
- Asserting the use of the compound in treating tumors, particularly targeting specific cancer types or pathways such as angiogenesis, apoptosis induction, or receptor blockade.
- Claims may specify methods of administering the compound or combinations with existing therapeutics.
-
Method Claims:
- Covering methods of synthesizing the compound, formulations, or delivery systems.
- These claims seek to protect proprietary manufacturing processes.
-
Combination Claims:
- The patent may claim the compound in combination with other agents (chemotherapy drugs, immune checkpoint inhibitors), broadening its scope.
Claim Breadth and Limitations
The patent’s claims are designed to balance broad protection with sufficient specificity to withstand legal challenges. Typically, Chinese patents in this domain include:
- Core compound claims with a detailed structure and specific substituents.
- Wyoming claims that extend to derivatives or analogs, creating a patent “family” for related compounds.
- Use and application claims to secure therapeutic indications.
The scope's breadth influences commercial deployment; overly narrow claims risk easy design-around, whereas overly broad claims could face invalidation if prior art exists.
Patent Landscape and Competitive Environment
Domestic Landscape
Within China, the patent landscape around anti-tumor agents is robust. Key players focus on:
- Novel small molecules targeting tyrosine kinases, PI3K/AKT/mTOR pathways, and immune checkpoints.
- Innovative biologics, including monoclonal antibodies and antibody-drug conjugates.
CN108135854 situates itself as part of this overarching ecosystem by claiming a potentially efficacious novel compound or therapeutic regimen.
International Landscape
While the patent is Chinese-specific, its claims’ scope, structural features, and intended indications can influence global patent strategies:
- Potential for Patent Families: The applicant could file corresponding applications under the Patent Cooperation Treaty (PCT) to extend protection internationally.
- Competitive Patents: Key competitors might hold analogous patents targeting similar mechanisms, creating a landscape wherein freedom to operate depends on claim differences.
Patent Prosecution and Litigation Trends
China’s patent office (CNIPA) employs examination standards that balance novelty, inventive step, and clarity, often favoring applicants with strong inventive disclosures [2]. As such, patents like CN108135854 could face challenges related to prior art, especially if early-stage compounds or mechanisms are well known.
Implications for Development and Commercialization
- Strategic Positioning: A broad, robust claim scope enhances the patent's defensive and offensive value, enabling exclusivity over specific chemical classes.
- Litigation and Licensing: Clear, distinct claims decrease litigation risk; a well-defined scope simplifies licensing negotiations.
- Innovation Dynamics: The patent landscape suggests a move toward combination therapies and personalized medicine, which should inform future R&D investments.
Regulatory and Market Considerations
In China, the patent’s enforceability, combined with regulatory approval pathways overseen by the National Medical Products Administration (NMPA), influences market entry strategies. The patent's claims' clarity and scope directly impact patent enforcement and potential market exclusivity.
Conclusion
CN108135854 reflects a strategic patent focused on a novel anti-tumor agent, with claims likely encompassing chemical structures, therapeutic applications, and formulation methods. Its positioning within China's active biotech patent environment underscores the importance of well-drafted claims to ensure broad protection while navigating potential prior art challenges.
Key Takeaways
- Scope of Claims: Precise delineation of chemical structures and therapeutic uses safeguards against design-arounds, while a balance is essential to withstand validity challenges.
- Landscape Significance: The patent sits amid intensive Chinese innovation in targeted oncology therapeutics, with implications for licensing, infringement risk, and future patent filings.
- Strategic Value: Broad and well-articulated claims can confer significant commercial advantage, especially when aligned with ongoing clinical development and regulatory approval.
- Infringement Risks: Overly narrow claims risk invasion; overly broad claims risk invalidation—necessitating strategic claim drafting.
- Global Patent Strategy: Given China's dynamic patent environment, applicants should consider filing related applications internationally to maximize market coverage.
FAQs
1. How does CN108135854 compare to similar patents in China's anti-cancer drug space?
It is comparable in scope, often focusing on specific chemical entities coupled with use in tumor treatment. Its novelty rests on the particular structure or application claims, which differentiate it from earlier patents or public disclosures.
2. Can the claims of CN108135854 be enforced internationally?
Not directly. For international protection, applicants need to file under the Patent Cooperation Treaty (PCT) or directly in target jurisdictions, referencing the Chinese priority to establish filing dates.
3. What challenges could CN108135854 face regarding patent validity?
Potential challenges include prior art that discloses similar compounds or applications, insufficient inventive step, or lack of novelty if the compounds or uses are previously known.
4. How might the patent landscape influence future innovation in Chinese oncology therapeutics?
The landscape encourages incremental innovation with focused claims, leading to a dense patent environment that requires strategic patent drafting and aggressive R&D to maintain competitive advantage.
5. What are the licensing prospects for technology protected by CN108135854?
High, especially if the compound demonstrates significant clinical efficacy. Licensing is often facilitated by comprehensive patent claims and clear therapeutic indications, which enhance market confidence.
References
- China National Intellectual Property Administration (CNIPA). (2023). Annual Report on Chinese Patent Applications in Biotechnology.
- WIPO. (2022). Patent Examination Procedures in China: Trends and Best Practices.
